Scarica l'app Stockscreener
17.37
0.00%
0.00
Pre-mercato:
17.51
0.14
+0.81%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Dyne Therapeutics Announces Submission of Biologics License Application to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy - Investing News Network
Dyne submits biologics license application for DMD treatment - Investing.com
Experimental Duchenne treatment from Dyne heads to FDA - Stock Titan
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - AOL.com
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside - MSN
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
How Investors Are Reacting To Dyne Therapeutics (DYN) Launching Phase 3 FORZETTO Trial For DYNE-251 - Sahm
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Dyne Therapeutics (DYN) director buys 2,500 Common Stock shares - Stock Titan
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission (DYN) - Seeking Alpha
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone - Yahoo Finance
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne Therapeutics, Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Dyne Therapeutics (DYN) Launches Phase 3 FORZETTO Trial for Duch - GuruFocus
Dyne Therapeutics Launches Late-Stage Trial for DMD Therapy - Intellectia AI
Dyne stock spikes as Duchenne trial launches (DYN:NASDAQ) - Seeking Alpha
DYN: 2026 will focus on DMD and DM1 launches, confirmatory trials, and pipeline expansion - TradingView
DYN: 2026 targets commercial launches for DMD and DM1, with pipeline expansion and strong clinical data - TradingView
Dyne Therapeutics launches phase 3 trial for DMD treatment - Investing.com UK
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval - Investing News Network
Dyne Therapeutics Initiates Phase 3 Trial of Potential Duchenne Muscular Dystrophy Treatment - Moomoo
Duchenne trial of z-rostudirsen tied to U.S. accelerated approval bid - Stock Titan
Dyne Therapeutics launches phase 3 trial for DMD treatment By Investing.com - Investing.com South Africa
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval - The Manila Times
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO - GlobeNewswire
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - The Motley Fool
MSN Money - MSN
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - Moomoo
DYN Maintained by Evercore ISI Group -- Price Target Lowered to $33 - GuruFocus
Janus Henderson reports 13.65M shares in Dyne Therapeutics (NASDAQ: DYN) - Stock Titan
T. Rowe Price (NASDAQ: DYN) holds 30.8M shares, a 18.7% stake - Stock Titan
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) CFO Sells 1,448 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Insider Sells $28,715.04 in Stock - MarketBeat
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):